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Summary The effects of '3'-labelled antiferritin polyclonal antibody for the treatment of established
hepatocellular carcinoma (HC-04) in athymic nude mice were evaluated. '3'I-labelled antiferritin antibody
localised specifically to a subcutaneous tumour with a mean of 8.1% of the infused dose per gram of tumour
at 24 h after infusion when the experiment was started 15 days after inoculation and with a mean of about
6.5% of the infused dose per gram of tumour when the experiment was started 30 days after tumour
transplantation. The concentrations of '3'I-antiferritin antibody in tumour delivered a mean of 1994cGy to
tumour following infusion of 500 9LCi of radiolabelled antiferritin antibody in the early group and a mean of
1600 cGy in the late group. Treatment with 5001tCi led to regression of the tumour in 55% of animals in the
early group and 44% in the late group. In contrast, unlabelled antiferritin and '3'-labelled IgG failed to exert
any significant effect on tumour growth.
The transplanted tumours in the early groups of animals had relatively higher concentration of ferritin than
those in the late group. There was accelerated inhibition of tumour growth and prolonged survival in animals
in the early group compared with those in the late group.
There is much controversy about the pharmacokinetics and
tumour uptake of radiolabelled antibodies. For example,
tumour growth was accompanied by a linear uptake of 1251-
labelled monoclonal antibody (MoAb) in a murine human
tumour system while the antigen of that model was not
detected in the circulation (Baldwin & Pimm, 1983). Enlarge-
ment of tumours was accompanied by a measurable decrease
in tumour concentration of "3'I-MoAb. This was a lymphoma
model which produced a circulating antigen (Menard et al.,
1983). An inverse relationship between tumour size and
antibody uptake has been reported (Moshakis et al., 1981).
Nonspecific antibody uptake varied directly with the tumour
size but was reduced by necrosis (Epenetos et al., 1982).
There may be some unidentified factors presumably related
to biological differences in tumour vascularity and or nec-
rosis. These factors may be responsible for the majority of
the tumour-to-tumour variation (Christopher et al., 1985).
Selective targeting of the tumours with radioactive antifer-
ritin has been used in clinical cases as well as in experimental
models (Order et al., 1986; Tang et al., 1990; Klein et al.,
1989; Moroz et al., 1989). Rostock et al. identified the
features that allow hepatocellular cancer to be targeted selec-
tively by '31I-antiferritin instead of the isotope being
deposited in the ferritin-bearing organs (Rostock et al., 1983,
1985). We have investigated the therapeutic effect of
radiolabelled antiferritin and have observed that the tumour
concentration of ferritin is relatively higher in the early phase
of tumour growth which helps to localise antibody, increases
the absorbed dose of radiation, improves treatment and pro-
longs survival.
Materials and methods
Human tumour xenograft model
Six to eight-week-old female athymic mice (nu/nu genotype,
BALB/c background) weighing 22-30 g were used in all
experiments. A ferritin-producing human hepatocellular car-
cinoma cell line (HC-04) was used; this was established and
has been maintained in our department (Kuwahara, 1980).
The animals were given subcutaneous (s.c.) injections in the
back with 0.1 ml of cell suspension containing 2 x 106 cells.
Tumours were visible within 15 days. Experiments were
started when the tumour nodule reached a diameter of
5- 10 mm.
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Antibody
Antiferritin polyclonal antibody (poly) was obtained from
Dakopatts, Denmark. Normal IgG (Jackson immunoresearch
USA) was used as control antibody.
Antibody radiolabelling
Polyclonal antiferritin and normal IgG were labelled with '"'I
and '25I (Amersham, England) by the lactoperoxidase glucose
oxidase method described by the manufacturer (Bio-Rad
Laboratories, Richmond, CA), at a labelling ratio of
5 mCi mg-'. The percentage of binding was determined by
trichloroacetic acid precipitation. All the procedures were
done under strict aseptic conditions and were tested for
pyrogens before injection.
Biochemical investigation
Biochemical investigation for ferritin in blood and in tumour
tissue was performed by immunoradiometric assay (IRMA)
from Otsuka Pharmaceuticals Japan.
Experimental design
The animals were divided into two groups: gr.A early and
gr.B late. Radiolabelled and unlabelled antibodies (Poly and
IgG) and saline solutions were administered intraperitoneally
15 days after inoculation in group A and 30 days after
inoculation in group B.
Antibody localisation
Biodistribution studies were performed by the double isotope
labelling method of Pressman (Pressman, 1957). Hepatocel-
lular carcinoma cells (2 x 106) were implanted s.c. on the
back of the mice. When the tumour grew to a diameter of
0.5-1.Ocm (about 15 days after inoculation), a mixture of
31I-labelled antiferritin antibody and '25I-labelled control
antibody was infused by intracardiac injection. At various
times (1, 6, 12, 24, 48 and 72 h) following infusion of the
labelled antibodies, a blood sample was obtained and mice
were sacrificed under ether anaesthesia. Tissues were excised,
weighed and counted in a multiple channel gamma counter
(Auto Gamma Model 5330 spectrometer; Packard Instru-
ments, Downers Grove, IL) to determine '3'I and 1251 activity.
The '25I counts were adjusted for crossover from the '3'I
channel by subtracting 14% of the '3'I channel counts from
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the '25I channel counts. Data were not corrected for decay of
either "3'I or 125I. All results were expressed as the percentage
of injected dose per gram of tissue (ID g-', mean ± s.e.) to
allow ready comparison of the proportion of administered
dose when varying quantities of antibody were given, or
varying iodination ratios were used. Absolute concentration
in tissues for a given infusion can be obtained by multiplying
this value by the dose administered, in jig or jiCi, to obtain
jig antibody g-' tissue or jsCi g-' tissue, respectively.
Radiation dosimetry
Radiation doses to various tissues from infusion of 131-
labelled antiferritin antibody and '3'I-labelled control IgG
were calculated from the biodistribution of labelled antibody,
assuming uniform distribution of isotope within individual
organs. The area under the biodistribution curve was
estimated from the mean percentage of ID g-' obtained for
each antibody at 1, 6, 12 h and 1, 2, 3, 6 and 8 days using the
trapezoidal integration method. Values for "3'I control
antibody were calculated by correcting the data obtained for
1251 control antibody to the values that would have been
obtained if the control antibody had been labelled with 13'I.
The initial concentration of radiolabelled antibody in all
tissues, except blood, was assumed to be 0% ID g-'. Initial
concentrations of antibody in blood were assumed to be
equivalent to the values at 1 h. Radiation doses were then
calculated for a 1,000jiCi initial antibody dose by multiply-
ing the integrated jiCi h-' g-' by the g.cGy iCi ' h-1, which
has been tabulated by the Medical Internal Radiation Dose
Committee (Dillman, 1969). For '3'I the value is 0.4165 for
the total of all P-particles, low energy X-rays and Auger
electrons, all of which are totally absorbed in the source
organ where the isotope is deposited. The major fy-ray for '3'I
is 0.364 MeV and deposits 0.6465 g.cGypjCi' hr-' but this
energy is poorly absorbed with only 10% deposited in a
sphere with a radius of 3 cm. Thus for the small organs in a
mouse, the y component to the absorbed dose has been
neglected. We elected to calculate cumulative radiation doses
by estimating the integral of the mean biodistribution curves
rather than by the effective half-life method for the reason
that, in several tissues, particularly tumour, uptake of
labelled antibody occurred over a 24-48 h period. Using the
trapezoidal method of integration results in a slightly higher
calculated radiation dose for portions of the clearance curves
that are concave and slightly lower doses for curves that are
convex compared to the effective half-life method. The
differences in calculated dose between the two methods are
small compared to the differences between animals that
would result from the variation in antibody concentrations in
tissues (Christopher et al., 1985).
Results
Concentration offerritin in tumour and blood
The level of ferritin in the blood and tissues of normal mice
was measured by IRMA. The serum level of ferritin was
0-30 ng ml-'; ferritin could not be detected in tissue from
the heart, lung, liver, spleen and kidney. Fifteen days after
inoculation of tumour, the mean blood level of ferritin was
10 ng ml' while the mean tumour concentration was
2,100ngmg-' protein. Thirty days after inoculation, the
mean level of ferritin in the blood was 70 ng ml-' and the
mean tumour concentration was 3,500 ngmg' protein. The
concentration of tumour ferritin tends to decline on day 40
after inoculation and that of blood ferritin on day 50 after
inoculation.
Antibody localization
The biodistribution of radiolabelled antibody was measured
after a single infusion. The localisation of '3'I-labelled antifer-
ritin antibody and '25M-labelled control antibody to tumour
and normal organs is shown in Figure 1.
The percentage of ID g'I of "3'I-labelled antiferritin in
tumour rose over the first 24 h, to a mean of 8.1% (range
2-15) in group A and 6.5% in group B and was maintained
at this level for approximately 24 h and thereafter declined
with a mean of 3.75% and 3.5% remaining at 8 days in
groups A and B respectively. In contrast, a mean of 1.8%
IDg-' (range 0.1-8.0) of control antibody was present in
tumour at 24 h and remained relatively constant over 8 days.
Clearance of both 13'I poly and 1251 control antibody from
blood, lung, liver and kidney demonstrated almost exponen-
tial decline over time and clearance rates were similar among
these tissues for both 13'I poly and 1251I control antibody.
Influence ofantibody dose on biodistribution
The influence of antibody dose on biodistribution was deter-
mined by infusing a single bolus over a 250-fold range from
10-2,500fig per animal and the concentration of 1311-poly in
tissues was determined 24 h after infusion (Figure 2). There
was no significant change (P = 0.43) in concentration of
'31I-polyclonal antiferritin in tumour as the dose varied from
10-400jg per animal. There was a significant decrease
(P = 0.05) in concentration of radioactive antibody in
tumour as the dose was increased from 400-2,500lig per
animal. In contrast, there was no evidence (P = 0.17) of
antibody dose influencing the concentration of radiolabelled
control antibody present in tumour over the range of
10-2,500jg per animal. However, the comparative study
between early and late administration indicated a relatively
significant increase in antibody concentration in tumour in
the case of "311-labelled antiferritin (P <0.05) but not 131I-
labelled control antibody.
There were no differences among doses in the proportion
of antibody localising to normal organs for either polyclonal
antiferritin, or control antibody (details not shown). The
biodistribution over time of total doses of antibody varying
from 10-1,000jig per animal was similar to that shown in
Figure 1. Thus, radiolabelled antiferritin, at a dose of up to
400 ig per animal, could be administered for maximum
localisation to tumour.
Toxicity and dosimetry
To determine the maximum nonlethal dose of "'lI antiferritin
polyclonal antibody, the mice received infusions of
500-2,000jiCi of 131I-labelled polyclonal antiferritin. All mice
survived following infusion of 500 or 1,000 iCi of 1311-
labelled polyclonal antiferritin. Approximately 50% of
animals died within 15-20 days after infusion of 1,500 iCi
with the remainder surviving more than 50 days. All of the
animals died within 2 weeks after infusion of 2,000jiCi.
Histological examination of animals receiving 1,000jCi of
'3'I-labelled antibody showed severe hypoplasia of the bone
marrow (approximately 15-20% normal cellularity) 2 weeks
after infusion, with recovery of marrow cellularity by day 25.
Administration of 500 iCi did not produce any sign of toxi-
city and, therefore, was the dose of choice in this experi-
mental study.
An approximation of the relative radiation doses that
would be delivered to tumour and critical normal tissues by
infusion of 1,000 Ci of '31I-labelled polyclonal antiferritin
was calculated from the biodistribution curves shown in
Figure 1, assuming uniform distribution of isotope in the
tumour and 100% absorption of all emitted P particles
(Table I). The inoculated tumours received a dose of ap-
proximately 4125cGy in group A and about 3300cGy in
group B. These results correlated to the difference in concen-
tration of ferritin and antiferritin antibody in tumours.
Therapy ofestablished tumour
The therapeutic effect of '3'I-labelled antibody was evaluated
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Figure 1 Biodistribution. Groups of BALB/c/nu/nu athymic mice received an intracardiac infusion of a mixture of 3'I-labelled
antiferritin polyclonal antibody and 25I-labelled irrelevant control antibody (normal IgG) on day 15 and day 30 following s.c.
inoculation of 2 x 106 HC-04 hepatoma cells. Individual mice were sacrificed at various times following infusion, and tissues were
excised, weighed and counted. Points are means of the percentages ofadministered dose g-' of tissue (% g-) for 3-20 animals per
time point; bars, s.e.. Data represent the results of four experiments with total antibody doses of 100-400 fig per animal.
Antibodies were labelled at iodination ratios of 0.005-0.02. For Tumour Chart: Antiferritin polyclonal antibody in Group A
(0 O) and in Group B (@ 0); Control antibody in Group A (0-*) and in Group B (0--0). For blood, lung,
liver, bone marrow and kidney: Polyclonal antiferritin Group A (0- *) and in Group B (0 -0); Control antibody in Group
A (0 O) and in Group B (0 0).
Table I Potential radiation doses delivered for 1,000jCi per
animal
'3'I-antiferritin '3'I-control antibody
Total dose (cGy) Total dose (cGy)
Organ Group A Group B Group A Group B
Blood 4000 3200 4200 4500
Tumour 4125 3300 935 750
Lung 1680 1350 2560 2050
Liver 1270 1020 1680 1350
Marrow 325 260 175 140
Spleen 680 540 525 420
Kidney 900 720 1280 1030
10 25 100 200 400 1000 2500
Antibody dose (Rg)
Figure 2 Effect of antibody dose on localisation to tumour.
From 10-2,500 gg (I/Ab, 0.01-0.05) of 3'I-labelled antiferritin
antibody and '251-control antibody were administered in Groups
A and B. Mean of the percentage of administered dose per g of
tumour 24 h after infusion. '3'I-antiferritin antibody in Group A
(0 O) and in Group B (0 0); 25I-control antibody in
Group A (0-- ) and in Group B (0-0) bars, s.e.
diameter (Table II). Infusion of 500 glCi of '31I-labelled
antiferritin led to complete disappearance of the s.c. nodule
in four out of 25 (16%) in group A and in three out of 25
(12%) in group B with partial regression in ten of 25 (40%)
in group A and eight of 25 (32%) in group B.
The survival curves of mice treated with 500 ICi '3'I-
labelled polyclonal antiferritin in group A and group B were
compared to those of a control group. Injections of 500fiCi
of "3'I-labelled polyclonal antiferritin in group B increased
median survival by 25% over control animals that had
received saline (P = 0.06). Administration of 500iLCi of ''I-
labelled polyclonal antiferritin in group A produced enhance-
ment of survival of greater statistical significance (P = 0.009)
(Figure 3).
Discussion
A high level of serum ferritin has been associated with
various neoplastic conditions, including hepatocellular car-
cinoma (Cohen et al., 1984, 1985; Kew et al., 1978; Nittsu et
al., 1975). Experimental and clinical investigations with
antiferritin antibody have been reported for tumour
targeting, imaging and immunoradiotherapy (Liu et al., 1988;
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able 11 "31-antibody therapy: established tumour treatment less effective. Although the mechanism of such
action is not well understood, it might be due to some
No. with interference by the higher concentration of blood ferritin.
No. with No. with partial & In these experimental studies, "3'I-labelled polyclonal
dose No. treated regression regression regression antiferritin specifically localised to a s.c. tumour mass in
concentrations sufficient to deliver a mean of approximately
15 0 (0). 0 (0) 0 (0) 4,125 cGy and 3,300 cGy to the tumours following infusion
Li 15 0 (0) 0 (0) 0 (0) of 1,000JACi of131I-labelled polyclonal antibody in groups A
lled) and B respectively. These results are comparable to the radia-
l 25 10 (40) 4 (16) 14 (56)b tion doses of 450 cGy following infusion of 500,tCi of '3'I-
ritin labelled antiferritin antibody in a rat hepatoma model
ij (Rostock et al., 1983). We have several other ferritin-
A) producing tumour lines of human hepatocellular carcinoma
i 25 8 (32) 3 (12) 11 (4)" and neuroblastoma (unpublished data) which revealed
ritin unusually high levels of tumour ferritin within the first few
1i B)weeks after inoculation although the serum level was normal.
B) An early process of development of a ferritin-producing
dy5
0 (0) 0 (0) 0 (0) tumour may not always be reflected by an increased level of
wlled) ferritin in the peripheral blood. In our previous experimental
5 0 (0) 0 (0) 0 (0) study, we tried to target a very small inoculated tumour,
dy ignoring the negative ferritin status of the blood. Administra-
'i tion of a very small dose of radioactive antiferritin (30i.Ci
? A) per mouse) showed a clear image of the inoculated tumour
5 0 (0) 0 (0) 0 (0) following scintigraphy (Une et al., 1989).
'i Nowadays, several imaging diagnostic methods are
2 B) available for the detection of early primary or metastatic
B)-control small lesions of human hepatocellular carcinoma but no
)ers in parentheses percentage. "Different from 'cn single method has proved completely accurate (Oren et al.,
1). (Fisher's exact test). 1986). Hepatic lesions less than 2.0 cm in diameter often give
false negative results and are therefore difficult to detect
(Lundstedt et al., 1985). Therefore, immunodetection using
radioactive antiferritin may provide a useful tool for the
detection of small, or early, lesions of hepatocellular car-
cinoma especially in the high risk group of patients. Only
12-16% of the animals treated with 500lCi of '31I-labelled
antiferritin showed complete regression. Since the surviving
tumour cells continue to express the ferritin antigen, im-
proved results require an increase in antibody concentration
,______,___,__,___,__,___1,______________ in tumour relative to normal organs. In this experimental
20 40 60 80 100 120 study, only a single dose of labelled antibody was given. The
Days prolonged retention of antibody in tumour, compared to the
concentration in blood and other organs, suggest that it
3 The survival curves of mice treated with 500 ItCi of shudbpoiletuemlile oesfanbdyo
Med ~. poylnlatfrii .ntbd nGopA(--- should be possible to use multipzle doses of antibody to
elled polyclonal antiferritin antibody in Group A(---aciv anices.ntmorcnetain
Group B (-----) compared to those of control (acheve an Increase In tumour concentration.
ed median survival of 25% in Group B over control There have been reports that requirements for therapy with
that had received saline (P = 0.06). Enhancement of radiolabelled antibodies are different from those for imaging
I of greater statistical significance (P = 0.009) over control (Larson et al., 1983; Leichner et al., 1983; Rostock et al.,
coxon-Gehan test. 1983). Our findings suggest a common requirement for treat-
ment and for imaging, that is, increased concentration of
tumour ferritin in the early phase of tumour growth.
al., 1986; Zhang et al., 1988). Specificity of antibody Therefore, we conclude that it is possible to equate the
Msified isotopic radiation may increase the tumour antigen expression as a function of tumour growth time with
position and tumour cytotoxicity (Klein et al., 1989). localisation of antibody and thus with radiation dosimetry
r, before, and after, treatment, the relationship from '31I-labelled antiferritin antibody and therapeutic re-
the level of blood and tumour ferritin and its effect sponses.
on the therapeutic response has not been clarified. Moreover,
the significance of the time of onset of therapy in terms of
the above factors has not been adequately explained.
We investigated the level of ferritin in blood and in tumour
at various intervals after inoculation of tumour cells. The
therapeutic response of antiferritin polyclonal antibody
appeared to be related primarily to the relative concentration
of ferritin in the tumour tissue. During the first few weeks
after inoculation, the concentration of tumour ferritin rose
progressively although the blood level remained normal. The
onset of treatment at this phase was more effective. On the
other hand, a relatively higher level of blood ferritin made
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